ALLO-316 is a gene-modified cell therapy commercialized by Allogene Therapeutics, with a leading Phase I program in Metastatic Renal Cell Carcinoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ALLO-316’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ALLO-316 is expected to reach an annual total of $32 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ALLO-316 Overview

ALLO-316 is under development for the treatment of acute myeloid leukemia, solid tumors and metastatic clear cell renal cell carcinoma. It is developed based on TALEN gene-editing technology and Dagger platform. The therapeutic candidate comprises of allogenic T cells engineered to express chimeric antigen receptor (CAR) consisting of an anti-CD70.

Allogene Therapeutics Overview

Allogene Therapeutics is a clinical stage biotechnology company that develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes UCART19, ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the shelf allogeneic CAR T therapy candidate for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. The company seeks to partner with other companies in the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.

The company reported revenues of (US Dollars) US$38.5 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$255.8 million in FY2021, compared to an operating loss of US$258.2 million in FY2020. The net loss of the company was US$257 million in FY2021, compared to a net loss of US$250.2 million in FY2020.

For a complete picture of ALLO-316’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.